Crystalline roxifiban
US6306886A · kind A · utility
3Cited by
1References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 15, 1998 |
| Grant date | Oct 23, 2001 |
| Priority date | — |
| Expiry date | Jun 15, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The potent platelet glycoprotein IIb/IIIa antagonist, roxifiban, is produced in crystalline form. Crystalline roxifiban exists in two polymorphic forms, designated Form 1 and Form 2. These polymorphic forms are characterized by x-ray powder diffraction and solid-state carbon NMR. Pharmaceutical compositions and methods for the treatment or prevention of diseases mediated by platelet aggregation are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.